The fact that hypertrophic cardiomyopathy is often familial has been known for a long time, and seven years ago the era of molecular cardiology opened up when hypertrophic cardiomyopathy in a large family was first linked to a locus on chromosome 14.1 Since this first report, major breakthroughs have been made in the understanding of the genetic background of this autosomal dominant disease. However, nobody anticipated the high degree of genetic heterogeneity observed in familial hypertrophic cardiomyopathy (FHC) , which is also seen in other familial cardiovascular disorders such as the long QT syndrome. Does the development of molecular biology offer the clinician an important new perspective on FHC ?
A high degree of genetic heterogeneity After the identification of the first locus on chromosome 14 qi1 -q12 (CMH 1), three other loci have been reported on chromosome 1q3 (CMH2), 15q2 (CMH3), and 1ip 13-q 3 (CMH4). Furthermore, in some families there is no evidence of a link with any of these loci, which suggests the existence of at least a fifth locus. In addition, in a particular form of FHC associated with a WolffParkinson-White syndrome, another locus has been identified on chromosome 7q3.
The morbid genes involved in FHC that have been identified encode proteins of the contractile apparatus: B myosin heavy chain (CMH1), cardiac troponin T (CMH2), a tropomyosin (CMH3), and the cardiac myosin binding protein C (CMH4).35 This finding was recently reinforced by the identification of mutations in the essential (chromosome 5) and the regulatory (chromosome 3) light chains of myosin associated with a rare variant of cardiac hypertrophy and abnormal skeletal muscle. 6 It is striking that all the morbid genes identified encode proteins of the sarcomere or proteins involved in the regulation of contraction. This observation suggests that FHC is a disease of the sarcomere and that ventricular hypertrophy, a major clinical characteristic of the disease, is a mechanism that compensates for depressed contractility. Indeed, some in vitro studies indicate that mutations in the B myosin heavy chain gene decrease the actin activated ATPase of myosin fragments and the actin translocation rate on the mutated myosin.78 These in vitro experiments are preliminary, however, and much additional work is needed to assess the functional consequences of the abnormal genes at the molecular and cellular levels.
More than 30 mutations have been identified in the B myosin heavy chain gene and several have also been reported in the genes encoding cardiac troponin T and a tropomyosin (see review in reference 9). This indicates considerable intragenic heterogeneity. In most instances, the molecular mechanism involved is a missense mutation with a nucleotide substitution changing one amino acid residue in the protein. Other types of mutations have also been reported in the genes for cardiac troponin T and cardiac myosin binding protein C.
Prognosis stratification Because the prognosis varies greatly from one family to another, it is important to determine whether or not the genetic heterogeneity accounts for the clinical diversity and to assess the relation between phenotype and genotype.
Various mutations of the B myosin heavy chain gene have been associated with a poor prognosis (malignant mutations rather than benign mutations). More generally, it has been proposed that mutations that change the electric charge of the amino acid residue are likely be malignant whereas neutral mutations are likely to be benign: conflicting results have been reported, however. This underlines the fact that large kindreds are needed for risk stratification and the need to create an international data base. 
